Compound ID | 1240
Class: Lipopolysaccharide synthesis inhibitor (LpxC inhibitor)
| Spectrum of activity: | Gram-negative |
| Details of activity: | Urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilisincluding multi-drug resistant strains |
| Institute where first reported: | Entasis Therapeutics |
| Highest developmental phase: | Preclinical |
| Development status: | Active |